Comment on “TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis”

We read with interest the individual patient data meta-analysis by Larrue et al. in which the authors demonstrate that the use of Transjugular Intrahepatic Portosystemic Shunt (TIPS) for refractory ascites and for prevention of variceal rebleeding reduces the incidence of a further decompensation event in comparison to standard of care (SOC) and increases survival in highly selected patients. [1] Larrue H. D'Amico G. Olivas P. Lv Y. Bucsics T. et al. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol. 2023 May 2; (00314-8 Epub ahead of print. PMID: 37141993): S0168-S8278https://doi.org/10.1016/j.jhep.2023.04.028 Abstract Full Text Full Text PDF Google Scholar Results of this paper are important because further reinforces the role of TIPS in the treatment of complications of portal hypertension. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysisJournal of HepatologyPreviewFurther decompensation represents a prognostic stage of cirrhosis associated with higher mortality than first decompensation. A transjugular intrahepatic portosystemic shunt (TIPS) is indicated to prevent variceal rebleeding and for refractory ascites, but its overall efficacy to prevent further decompensations is unknown. This study aimed to assess (i) the incidence of further decompensation and (ii) mortality after TIPS vs. standard of care (SOC). Full-Text PDF